Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of TST001 in CLDN18.2-positive advanced cholangiocarcinoma
ChiCTR2100054990Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osemitamab in cholangiocarcinoma (CCA) and biliary neoplasm, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate. Started Jan 2022; status: completed.
02
Drugs
osemitamab
03
Conditions
cholangiocarcinoma (CCA)biliary neoplasm
Beyond the preview
Go deeper on ChiCTR2100054990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054990.